Scleroderma

February 15, 2016February 18, 2016

In Certain People with PAH, Researchers Identify Markers for Lower Mortality Rates

News, Pulmonary Hypertension, Scleroderma

A new study demonstrated that specific antibodies could be markers for decreased mortality in people with connective tissue disease and systemic sclerosis associated with pulmonary arterial hypertension (PAH). The report in ... Read more

February 4, 2016February 4, 2016

Study of 2 Lung Diseases Shows No Genetic Link

News, Pneumonia, Scleroderma

A new study reports that although lung disease in systemic sclerosis (SSc) shares similarities with idiopathic interstitial pneumonia, the disorders do not have a common genetic basis. The article, titled ... Read more

December 10, 2015December 10, 2015

Phase 3 Trial for Systemic Sclerosis with Lung Fibrosis Enrolls 1st Patient

News, Scleroderma

Boehringer Ingelheim announced the enrollment of the first patient in its global, double-blind, randomized and placebo-controlled SENSCIS Phase 3 clinical trial. The trial (NCT02597933), is open for patient recruitment, and is evaluating the safety ... Read more

September 15, 2015November 6, 2015

Cytori Therapeutics’ Scleroderma Therapy Shows Promising Results After 12 Months of Treatment

News, Scleroderma

Cytori Therapeutics a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently announced the results from a 12-month follow-up of patients ... Read more

September 11, 2015November 6, 2015

FVC Found To Be An Unreliable Predictor of Interstitial Lung Disease in Scleroderma Patients

Idiopathic Pulmonary Fibrosis, News, Scleroderma

A negative diagnosis can be relieving for many individuals, but occasionally in scleroderma, individuals with interstitial lung disease are wrongly diagnosed as healthy according to pulmonary function tests. In a ... Read more

August 20, 2015November 6, 2015

Resunab Receives Fast Track FDA Status To Treat Scleroderma

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development firm committed to addressing chronic, rare and serious inflammatory and fibrotic diseases, recently announced that the United States Food and Drug Administration (FDA) has ... Read more

July 31, 2015November 6, 2015

Study Determines That SSc May Not Be a Progressive Disease in All Cases

News, Scleroderma

In a study recently presented during the European League Against Rheumatism Annual European Congress of Rheumatology (EULAR 2015), a team of researchers found that fatigue and functional limitations remained stable ... Read more

July 23, 2015November 6, 2015

Systemic Sclerosis Patients Found To Have Higher Risk for Temporomandibular Joint Disorder

News, Scleroderma

In a recent study, researchers observed that temporomandibular joint disorder is common in Systemic Sclerosis patients, correlating with disease severity. The findings were presented at the European League Against Rheumatism Annual European ... Read more

July 2, 2015November 6, 2015

Study Presented at EULAR Shows Roche’s Esbriet Meets Safety Targets in Systemic Sclerosis-related Interstitial Lung Disease

News, Scleroderma

Results from a recent open-label trial presented during the European League Against Rheumatism Annual European Congress of Rheumatology showed that ESBRIET met its safety endpoint in the treatment of interstitial lung ... Read more

June 15, 2015November 6, 2015

Corbus Announces FDA Orphan Drug Designation For Resunab To Address Systemic Sclerosis

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug advancement company focused on addressing chronic rare and serious fibrotic inflammatory diseases, announced recently that the United States Food and Drug Administration (FDA) has granted Corbus’ lead candidate ... Read more